AI-Powered Drug Discovery Efforts Could Lead to New Treatments

Stephen Abreu, Sidley partner, talks to Colin Hill, CEO and Co-Founder of AI-powered drug discovery company Aitia, about how the use of AI is revolutionizing the biotech space.

(more…)

Europe’s Regulatory Approach to Continuous Learning AI

The regulation of continuous learning models involves the challenge of navigating the future. The EU is striving to stay ahead of the game with its forthcoming AI Act and harmonised standards. Eva von Mühlenen, Oliver Haase of Validate, and Leon Doorn of Aidance discuss.

Innovation, Collaboration, and Access to Capital: Key Takeaways from the Sidley Healthcare Investment Conference

At Sidley’s Healthcare Investment Conference on 12 September, speakers analysed the flow of capital across the global life sciences and healthcare ecosystem in panels discussing collaborative deals, sources of funding, the regulatory scrutiny of deals, and women’s health.

Five Governance Steps To Consider When Using Generative AI Within A Pharma Company

Pharma companies are looking to better understand how Generative AI (GAI) can facilitate innovation. Early adopters can gain distinct advantages while properly managing the top-of-mind potential risks discussed below. Francesca Blythe and Steve McInerney explain the corporate governance principles that should be considered.

Start Thinking About Human Rights and Environmental Impact of Subsidiaries and Value Chains

The impending EU Corporate Sustainability Due Diligence Directive (“CS3D”) means most EU and some non-EU life sciences companies should begin to assess their wider human rights and environmental impacts and rethink compliance programmes. Michele Tagliaferri explains.

Four Tips for Successful Development of Cell and Gene Therapies

Developing a cell or gene therapy (CGT) involves a range of regulatory considerations and challenges. Emily Marden and Jaclyn Fonteyne point to some key factors that are currently the focus of FDA attention and may merit consideration by sponsors early in the development process.

Seven Things Life Sciences Buyers and Sellers Should Know About CVRs

The life sciences industry has recently seen a proliferation of Contingent Value Rights (CVRs), the public M&A equivalent of the earnout used in private deals.  Sally Wagner Partin, Sharon Flanagan, and Hannah Brown explain what you need to know about them.

Resources

 

Upcoming Events

SUBSCRIBE

To receive email alerts when we post a blog entry, please provide your name and email address.

Archives

Categories